DCM
AZN icon

Delpha Capital Management’s AstraZeneca AZN Stock Holding History

Delpha Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,186
Closed -$152K – 222
2017
Q4 		$152K Buy
+2,186
New +$147K 0.17% 81

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Delpha Capital Management's AZN Position: Q1 2018 in Review

Delpha Capital Management sold out of AstraZeneca (AZN) in Q1 2018, closing a stake of 2,186 shares — an estimated $152K sold.

Delpha Capital Management first reported a position in AZN in Q4 2017 and held it in 1 quarter. The position peaked at $152K in Q4 2017. 519 funds tracked by Wall St. Rank hold AZN as of Q1 2018.

  • Delpha Capital Management reported no remaining AstraZeneca position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 2,186 AstraZeneca shares in Q1 2018, an estimated $152K.
  • Delpha Capital Management first reported a position in AstraZeneca in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's AstraZeneca position peaked at $152K in Q4 2017.
  • 519 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.